Robinul

Drooling, peripheral muscarinic effects, cardiac vagal inhibitory reflexes + 16 more

Treatment

20 Active Studies for Robinul

Treatment for

Drooling

What is Robinul

Glycopyrronium

The Generic name of this drug

Treatment Summary

Glycopyrronium is a medication used to treat various conditions and is made up of two enantiomers, which are both quaternary ammonium compounds. It works by blocking signals from the nerves to the muscles, reducing secretions from sweat, oral, airway and gastric glands, and reducing cardiac inhibitory reflexes. It is used to treat peptic ulcers, reduce bronchoconstriction in COPD, and is considered to have a wider therapeutic window than tiotropium. Glycopyrronium was approved by the FDA in 1961 and is one of the most commonly prescribed anticholinergic medications

Robinul

is the brand name

Robinul Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Robinul

Glycopyrronium

1961

294

Effectiveness

How Robinul Affects Patients

Glycopyrronium is a medication used to block certain signals of the nervous system. It is effective for a long time and is considered safer than other similar medications. However, patients should be aware of the potential risks, such as worsening urinary retention, overheating, and blurred vision.

How Robinul works in the body

Glycopyrronium is an anti-muscarinic drug that blocks the M1, M3, M2/M4, and M5 muscarinic receptors. Muscarinic receptors in the lungs are mainly responsible for narrowing airways and producing mucus. They also help control the amount of saliva and sweat produced, as well as the acidity of stomach acid. By blocking the muscarinic receptors, glycopyrronium reduces mucus and saliva production, and decreases the acidity of stomach acid. It also blocks the vagal nerve, which normally slows down your heart rate, which can lead to a slower

When to interrupt dosage

The prescribed dosage of Robinul relies upon the determined condition, for example, Peptic Ulcer, Neurological Conditions and Drooling. The amount of dosage is contingent upon the strategy of delivery (e.g. Capsule - Respiratory (inhalation) or Aerosol, metered) as presented in the table beneath.

Condition

Dosage

Administration

Drooling

, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg

, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating

Increased upper airway secretion

Induction of anesthesia therapy

Choking

Bronchitis, Chronic

Peptic Ulcer

General Surgery

Cerebral Palsy

Hyperhidrosis disorder

Oral cavity

Anticholinergic Syndrome

Reflex, Trigeminocardiac

Chronic Obstructive Pulmonary Disease

peripheral muscarinic effects

cardiac vagal inhibitory reflexes

Bodily secretions

Emphysema

Neurological Conditions

Warnings

Robinul Contraindications

Condition

Risk Level

Notes

Ulcerative Colitis

Do Not Combine

Uterine Inertia

Do Not Combine

Ulcerative Colitis

Do Not Combine

Myasthenia Gravis

Do Not Combine

Arterial Occlusive Diseases

Do Not Combine

Cardiovascular Physiological Phenomena

Do Not Combine

Pulse Frequency

Do Not Combine

Therapeutic procedure

Do Not Combine

Intestinal Pseudo-Obstruction

Do Not Combine

Open-angle glaucoma

Do Not Combine

Uropathy Obstructive

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Glycopyrronium may interact with Pulse Frequency

There are 20 known major drug interactions with Robinul.

Common Robinul Drug Interactions

Drug Name

Risk Level

Description

Aclidinium

Major

The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Aclidinium.

Cimetropium

Major

The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Cimetropium.

Eluxadoline

Major

The risk or severity of constipation can be increased when Glycopyrronium is combined with Eluxadoline.

Macimorelin

Major

The therapeutic efficacy of Macimorelin can be decreased when used in combination with Glycopyrronium.

Secretin human

Major

The therapeutic efficacy of Secretin human can be decreased when used in combination with Glycopyrronium.

Robinul Toxicity & Overdose Risk

Taking too much Atropine can cause flushing, fever, an increased heart rate, difficulty urinating, sensitivity to light, enlarged pupils, nausea, vomiting, dizziness, feeling faint, and constipation. The toxic dose for mice is 570 mg/kg when taken orally, and 709 mg/kg when taken by mouth in rats. When given through an injection in mice, the toxic dose is 90 mg/kg, and 196 mg/kg in rats. Patients should be treated with supportive care such as catheters to manage urinary retention, cardiovascular support, and ventilation, if needed.

Robinul Novel Uses: Which Conditions Have a Clinical Trial Featuring Robinul?

164 active clinical trials are investigating the potential of Robinul to alleviate symptoms of Chronic Obstructive Pulmonary Disease (COPD), cardiac vagal inhibitory reflexes and for use in General Surgery.

Condition

Clinical Trials

Trial Phases

Chronic Obstructive Pulmonary Disease

77 Actively Recruiting

Phase 3, Phase 1, Phase 2, Not Applicable, Early Phase 1, Phase 4

Choking

4 Actively Recruiting

Not Applicable

General Surgery

2 Actively Recruiting

Not Applicable

Hyperhidrosis disorder

0 Actively Recruiting

Increased upper airway secretion

0 Actively Recruiting

Anticholinergic Syndrome

0 Actively Recruiting

Induction of anesthesia therapy

0 Actively Recruiting

Reflex, Trigeminocardiac

0 Actively Recruiting

Emphysema

4 Actively Recruiting

Phase 2, Not Applicable

Oral cavity

0 Actively Recruiting

peripheral muscarinic effects

0 Actively Recruiting

Reflex, Trigeminocardiac

0 Actively Recruiting

Drooling

0 Actively Recruiting

Neurological Conditions

1 Actively Recruiting

Not Applicable

Bronchitis, Chronic

0 Actively Recruiting

cardiac vagal inhibitory reflexes

0 Actively Recruiting

Peptic Ulcer

0 Actively Recruiting

Bodily secretions

0 Actively Recruiting

Cerebral Palsy

0 Actively Recruiting

Patient Q&A Section about robinul

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How long does it take Robinul to work?

"Studies have shown that glycopyrrolate is safe and effective in treating hyperhidrosis, with results typically observed within one week."

Answered by AI

What are side effects of Robinul?

", headache, muscle aches, cramps;, itching;, decreased appetite;, increased appetite;

The text lists a number of potential side effects that may occur after taking medication. These include constipation, nausea, vomiting, bloating, drowsiness, dizziness, weakness, feeling nervous, slow heartbeats, sleep problems, blurred vision, sensitivity to light, dry mouth, decreased sense of taste, decreased sweating, decreased urination, impotence, sexual problems, headache, muscle aches, cramps, itching, decreased appetite, and increased appetite."

Answered by AI

What does Robinul do to heart rate?

"ROBINUL works by blocking an enzyme in the nervous system that is responsible for producing saliva in your mouth and secretions in your stomach and lungs. This enzyme also slows down the heart rate. When this enzyme is blocked, secretions dry up and the heart rate increases."

Answered by AI

What is the drug Robinul used for?

"Glycopyrrolate belongs to a class of drugs named anti-cholinergics.

Glycopyrrolate is used in combination with other drugs to treat peptic ulcers, which are a type of stomach or intestinal ulcer. This medication may help relieve pain in the stomach or abdomen. Glycopyrrolate is a type of drug known as an anticholinergic."

Answered by AI

Clinical Trials for Robinul

Image of Stanford University in Stanford, United States.

MoblO2 for Chronic Lung Diseases

18+

All Sexes

Stanford, CA

Many patients with chronic lung disease (e.g., chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD)) require supplemental oxygen (O2) at some point during their disease course. Practitioners prescribe O2 to patients with chronic lung disease in hopes of the following: 1) that it will limit desaturation events and combat breathlessness, thus preventing the frustratingly slow pace and numerous rest breaks patients are forced to adopt while doing even simple tasks; 2) that it will allow patients to be more active physically (perhaps increase their ability to exercise) and socially (perhaps leave the home more often); 3) that it will stave off putative complications of hypoxemia (e.g., cognitive dysfunction, pulmonary hypertension) and 4) that it will improve health-related quality of life (HRQL). However, despite the rationale for O2, and prescribers' good intentions, patients generally view O2 with frustration and fear - it threatens their HRQL, which is already impaired by having a condition that imposes itself on every aspect of their lives. Nasal cannulas and delivery devices call unwanted attention to patients when they are out in public. O2 users feel stigmatized and are often viewed as "smokers who get what they deserve, even if they never smoked a day in their lives" - or as disabled, sick or even infectious. O2 steals patients' independence, forcing them to plan their lives around it. The anxiety that patients and their caregivers experience around running out of oxygen, or not getting enough, immobilizes them and restricts participation in activities outside of the home. O2 disrupts the home environment, adding stress, and creating a burden for patients' caregiver-loved-ones who are often saddled with the responsibility of ensuring adequate equipment and supply of O2, and O2 is a constant reminder to patients they are living with a condition that could shorten their lives. O2 delivery equipment is typically heavy, unwieldy and intimidating. Different recommendations (e.g., insurance companies use 88% as a cut-off for SpO2, while many practitioners focus on 90%) make it confusing for patients, which almost certainly affects adherence. O2-requiringpatients are starving for things that can make their lives easier. An auto-adjusting O2 delivery device - one that automatically delivers the correct amount of O2 to maintain blood oxygen at desired, pre-set levels - would alleviate the need for patients to constantly (incessantly for many) monitor their peripheral oxygen saturation (SpO2) and adjust O2flow to meet the demands as exertion levels vary . The MoblO2 device is a battery-operated, light-weight, closed-loop O2 delivery device that houses a regulator (which attaches to compressed gas O2 tanks) and adjusts O2 flow to meet a pre-set blood oxygen level. A pulse oximeter is worn on the ear and transmits via Bluetooth to the device, which adjusts an internal valve to control flow on a second-to-second basis. The user sets the dial to the highest flow of O2 needed to meet the demands of activities they might perform (up to 15 liters per minute), and the device adjusts flow, up to the pre-set level to maintain SpO2 at a preset level (e.g., \> 90%). To conserve O2 supply in the tank - and to avoid over-oxygenation (which could be problematic for a small percentage of patients with the most severe COPD) - the MoblO2 begins to limit O2 flow at a SpO2 of 93%. The device can be manually over-ridden by the user, and should the battery run out - or the device fail for some unforeseen reason - the default position is valve open, so the users receive whatever flow of oxygen has been set on the dial. Given the substantial burdens of O2 on patients and their families, the hassles patients describe with having to monitor their SpO2 and repeatedly adjust the flow of O2 to meet their needs, patients and experts around the world have called for improvements in O2 delivery equipment. The MoblO2 is just such a remarkable improvement and a giant step forward in helping to ease the burdens of O2 on patients who require it. The purpose of this study is to investigate the effects of the MoblO2 O2 delivery device on a range of outcomes, including physical activity, amount (liters) O2 use; maintenance of adequate SpO2 levels; patient reported outcomes including symptoms, HRQL and satisfaction with the MoblO2 O2 device.

Waitlist Available

Has No Placebo

Stanford University

Jeff Swigris, DO, MS

Minnesota Health Solutions